soul trial oral semaglutide cardiovascular outcomes 2024 nejm 2025 🔴 Cardiovascular with by severity of chronic kidney disease in type 2 diabetes: the soul trial oral semaglutide cardiovascular – NEJM Editorial Fellow Harleen Marwah,

This is substantially less than the 3-15 grams used in oral supplementation studies, but the injectable route provides direct systemic delivery that bypasses gastrointestinal absorption losses

Reduced appetite on Wegovy increases the risk of insufficient protein intake, which can contribute to loss of lean muscle mass alongside fat loss

Lim SW, Jin L, Jin J, Yang CW

Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials

The main risk with switching from a compounded to name-brand GLP-1 is from transitioning straight to a high dose (even if on a higher dose of a compounded version), given the risk for potential increased side effects and intolerance, says Stanley

Effects of fecal microbiota transplantation with oral capsules in obese patients